2022³â ´ëÇѹ财Àå¾Ö¿ä½Ç±ÝÇÐȸ Á¦27Â÷ Çмú´ëȸ (1ÀÏÂ÷) : 2022-09-02±³À°ÀÏÀÚ : 2022-09-02
±³À°Àå¼Ò : À̴뼿ﺴ¿ø ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç
±³À°ÁÖÁ¦ :
2022³â ´ëÇѹ财Àå¾Ö¿ä½Ç±ÝÇÐȸ Á¦27Â÷ Çмú´ëȸ (1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѹ财Àå¾Ö¿ä½Ç±ÝÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574
À̸ÞÀÏ :
app@app2010.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 110,000¿ø
ºñ°í Àü¹®ÀÇ(ȸ¿ø-¿¬È¸ºñ³³ºÎÀÚ) »çÀüµî·Ï50,000/ÇöÀåµî·Ï60,000 * Àü¹®ÀÇ(ȸ¿ø-¿¬È¸ºñ¹Ì³³ÀÚ) »çÀüµî·Ï100,000/ÇöÀåµî·Ï110,000* Àü¹®ÀÇ(ºñȸ¿ø) »çÀüµî·Ï100,000/ÇöÀåµî·Ï110,000 * °£È£»ç(ȸ¿ø-¿¬È¸ºñ³³ºÎÀÚ) »çÀüµî·Ï30,000/ÇöÀåµî·Ï40,000 * °£È£»ç(ȸ¿ø-¿¬È¸ºñ¹Ì³³ÀÚ) »çÀüµî·Ï80,000/ÇöÀåµî·Ï90,000 * °£È£»ç(ºñȸ¿ø) »çÀüµî·Ï80,000/ÇöÀåµî·Ï90,000 * ±ºÀÇ°ü,°øº¸ÀÇ,Àü°øÀÇ,ÀÇ°ú,°£È£´ëÇлý / »çÀüµî·Ï ¹«·á , ÇöÀåµî·Ï 40,000* 65¼¼ ÀÌ»ó ȸ¿ø / »çÀüµî·Ï ¹«·á. ÇöÀåµî·Ï ¹«·á(»çÀüµî·Ï¿¡ ÇÑÇÔ)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 08:30~09:00 Registration ()
±âŸ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 09:00~09:05 Opening Remarks ()
±âŸ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 09:05~09:10 Congratulatory Remarks ()
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 09:10~09:30 Pros ½ÅÁ¤Çö(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 09:30~09:50 Cons °í±¤Áø(¼º±Õ°üÀÇ´ë)
Åä·Ð 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 09:50~10:10 Panel discussion ()
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 10:10~10:40 Minimal invasive treatment of small BPH: Is HOLEP still the gold standard ±è¸í±â(ÀüºÏÀÇ´ë)
ÈÞ½Ä 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 10:40~11:00 Coffee Break ()
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 11:00~11:15 Refractory nocturia: poor efficacy or side effect of desmopressin Á¶¿µ»ï(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 11:15~11:30 Recurrent simple UTI ÃÖÈÆ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 11:30~11:45 Recurrent gross hematuria after pelvic radiation therapy ½Åµ¿±æ(ºÎ»êÀÇ´ë)
Åä·Ð 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 11:45~12:05 Panel discussion ()
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 12:05~13:00 Current status of the combination pills for LUTS Ã߹μö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 13:00~13:20 Mechanisms of stress affecting lower urinary tract symptoms À±Çϳª(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 13:20~13:40 Immune-related diseases and lower urinary tract symptoms ±ÇÁعü(´ë±¸ÆÄƼ¸¶º´¿ø)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 13:40~14:00 Diverse pathophysiologies focused on OAB ½ÅÁÖÇö(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 14:00~14:30 Persistent BOO and bladder dysfunction ±è¼öÁø(ÇѸ²ÀÇ´ë)
±âŸ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 14:30~14:45 Desmopressin Áø·áÁöħ ¹ßÇ¥ ¿©Á¤±Õ(ÀÎÁ¦ÀÇ´ë)
ÈÞ½Ä 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 14:45~15:05 Coffee Break ()
±âŸ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 15:05~15:20 Report from The Committees: Public Relations Committee ¹èÀçÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 15:20~15:50 Pathophysiology & novel pharmacological targets for underactive bladder ±è¾Æ¶÷(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 15:50~16:10 Issue 1: Patients with CP/CPPS Á¶Àη¡(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 16:10~16:30 Issue 2: Patients with IC/BPS ±è¿µÈ£(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 16:30~16:50 Issue 3: Patients with neurogenic bladder ¿À½ÂÁØ(¼¿ïÀÇ´ë)
Åä·Ð 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 16:50~17:20 Panel discussion ()
±âŸ 09-02 ÄÁº¥¼Ç¼¾ÅÍ ´ë°´ç 17:20~17:30 Closing Remarks & Group photo ()